For the first time, the combination of pertuzumab, trastuzumab, and docetaxel has been tested in patients with HER2-mutated advanced non-small cell lung cancer (NSCLC). Triple therapy is widely used for the management of HER2-positive breast cancer. The study was reported by Prof. Julien Mazieres, Pneumology, CHU Toulouse—Hôpital Larrey, Universite
976 Reached1 Comments
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Case of Pulmonary Embolism with Syncope
544 Reached4 Likes
Black Lesion in Old Female
1966 Reached5 Comments11 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1006 Reached2 Comments